Dissecting Isoform Selectivity of PI3 Kinase Inhibitors. Uncovering leads for rational drug design.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/545943

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The PI3 kinase enzyme controls many functions in cells and in many cases contributes to the onset and progression of diseases such as cancer, thrombosis and inflammatory diseases. Compounds that block PI3 kinase activity may be useful drugs but will need to act specifically to minimize side effects. We aim to understand the way in which inhibitors block the PI3 kinase activity with the belief that this information will allow us to make better drugs.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $518,989.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Enzymes

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer | cancer chemotherapy | cancer therapy | colorectal cancer | drug design | kinase inhibitors | kinases | medicinal chemistry | oncogene

Related Links